专题：《钱道》：对话上市公司掌门人 在对话中，华熙生物董事长赵燕表示，和年轻人在一起的时候，除了好奇、勇气和坚韧，还需要了解到 他们在关注什么，认真去分析底层原因。 她谈到，科技进步到了现在，年轻人获得信息的触点很多，所以他们对一件东西看中的不是价值有多 高，而是一定要触动他的情绪点，让他愿意去消费，哪怕再难、再贵。 赵燕强调，尤其是企业做研发，一定要观察现在有哪些消费者的需求是未被满足的，而且一定要能够打 动他的情绪连接点。"比如像衰老，很多女性为了悦己者容，需要别人来喜欢自己。但今天我们产品设 计的出发点是'女为悦己容'，就是为取悦自己而愿意变得美丽。" 她表示，大家都说"年轻人活得比较自我"，这没错。"如果他对自己都不好，你很难指望他对别人好。" 由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 在15分钟精华对话中，坦诚分享如何识别 组织衰老、推动认知对齐、重建执行逻辑。#透过财经看世界# 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着 ...

专题：《钱道》：对话上市公司掌门人 在对话中，谈及一个组织衰老的致命原因时，华熙生物董事长赵燕表示，组织和生命体是一样的，组织 的衰老是源于领导者将过往的经验带到了这个组织当中，但是环境变了，经验没有跟着变化。 赵燕特别指出，尤其是成功的企业，他们抱着"我这条路径是成功的"想法，产生了路径依赖，不去看外 部环境发生了哪些变化，消费者发生了哪些变化。她以华熙生物为例，谈到华熙生物是一家创新驱动的 企业，按道理来说，它对前沿的东西应该是最敏锐的，而且对于消费者市场的需求，也应该是最敏锐 的。一定要时时刻刻保持观察到消费者未被满足的需求在哪，而不是去跟风市场上的需求。 "衰老是能传染的，组织内部尤其这样。一旦出现了这样的现象，一个小点就能扩散到一条线，一条线 就能扩展到一个面。"她说。 由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 在15分钟精华对话中，坦诚分享如何识别 组织衰老、推动认知对齐、重建执行逻辑。#透过财经看世界# 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递 ...

专题：《钱道》：对话上市公司掌门人 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 责任编辑：李昂 专题：《钱道》：对话上市公司掌门人 在对话中，谈及衰老的话题，华熙生物董事长赵燕坦言，"每个人对衰老都有担忧，但是我不害怕。" 赵燕表示，大家都认为衰老是一个自然过程，但是在生命科学领域来说，衰老是能够被主动干预和控制 的过程。容颜的衰老它只是一个表面，要更关注"生命的延长"，怎么样有质量地活得长。 在对话中，谈及衰老的话题，华熙生物董事长赵燕坦言，"每个人对衰老都有担忧，但是我不害怕。" 赵燕表示，大家都认为衰老是一个自然过程，但是在生命科学领域来说，衰老是能够被主动干预和控制 的过程。容颜的衰老它只是一个表面，要更关注"生命的延长"，怎么样有质量地活得长。 她提到，女人有"三怕"：怕老、怕丑、怕死。随着生命科学的发展，这三个方面都是能够去有效地控制 的。华熙生物的使命，是让每个生命都是鲜活的，所以要提高生命质量，让人活得长。"医美说到底， 是让人重拾自信，尤其对于女性，能够很优雅地变老，更多的是一个心理上的慰藉。" 由@新浪 ...

在对话中，谈及衰老的话题，华熙生物董事长赵燕坦言，"每个人对衰老都有担忧，但是我不害怕。" 赵燕表示，大家都认为衰老是一个自然过程，但是在生命科学领域来说，衰老是能够被主动干预和控制 的过程。容颜的衰老它只是一个表面，要更关注"生命的延长"，怎么样有质量地活得长。 她提到，女人有"三怕"：怕老、怕丑、怕死。随着生命科学的发展，这三个方面都是能够去有效地控制 的。华熙生物的使命，是让每个生命都是鲜活的，所以要提高生命质量，让人活得长。"医美说到底， 是让人重拾自信，尤其对于女性，能够很优雅地变老，更多的是一个心理上的慰藉。" 由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 在15分钟精华对话中，坦诚分享如何识别 组织衰老、推动认知对齐、重建执行逻辑。#透过财经看世界# 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 专题：《钱道》：对话上市公司掌门人 责任编辑：李昂 专题：《钱道》：对话上市公司掌门人 责任编辑：李昂 在 ...

由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 坦诚分享企业抗衰、人心凝聚与科学坚 守。 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 专题：《钱道》：对话上市公司掌门人 在被问到那场"战争"，华熙生物董事长赵燕称有点遗憾的是，私底下支持的人还是不少，但是没有人敢 站出来，公开地大家形成一个行业的共识。她认为科技要给我们带来平权，未来10年重大的疾病都能够 有办法来治愈，人只要为自己的健康负责，都能够活超过120岁。 责任编辑：李昂 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 责任编辑：李昂 由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 坦诚分享企业抗衰、人心凝聚与科学坚 守。 专题：《钱道》：对话上市公司掌门人 在被问 ...

新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 责任编辑：李昂 专题：《钱道》：对话上市公司掌门人 专题：《钱道》：对话上市公司掌门人 在被问到华熙生物衰老了吗？华熙生物董事长赵燕承认组织内部确实出现问题，敏锐度不够，但不害怕 衰老。对于为行业发声有没有后悔过，她坦言没后悔过，希望回归理性。2025年，她认为自己像是 个'圣斗士'，2026年，我们问她：华熙"轻舟已过万重山"了吗？她说：还不能这么说。 由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 在15分钟精华对话中，坦诚分享如何识别 组织衰老、推动认知对齐、重建执行逻辑。#透过财经看世界# 由@新浪财经、微博联合打造，@微博财经 #达芬奇live# 出品的对话栏目#钱道# 第一期，邀请华熙生 物董事长赵燕，与英才元投资管理有限公司董事长@宋立新 在15分钟精华对话中，坦诚分享如何识别 组织衰老、推动认知对齐、重建执行逻辑。#透过财经看世界# 新浪声明：所有会议实录 ...

证券之星消息，2月24日医疗美容板块较上一交易日上涨0.26%，华熙生物领涨。当日上证指数报收于 4117.41，上涨0.87%。深证成指报收于14291.57，上涨1.36%。医疗美容板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 从资金流向上来看，当日医疗美容板块主力资金净流出1654.49万元，游资资金净流入562.75万元，散户 资金净流入1091.74万元。医疗美容板块个股资金流向见下表： ...

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential anti-aging benefits, DNA repair, and metabolic regulation, with significant regulatory advancements expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial applications, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2][19]. NMN Definition and Function - NMN is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - As NAD+ levels decline with age, NMN supplementation can quickly elevate NAD+ levels, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4][6]. Regulatory Environment - The global regulatory landscape for NMN is shifting from strict restrictions to cautious openness, with significant milestones achieved in various countries [17][18]. - In China, NMN has been approved as a new cosmetic ingredient and is on the path to being recognized as a health food, with the National Market Supervision Administration listing it for health food approval in April 2025 [17][18]. Market Demand - The aging population in China is expected to grow significantly, with the elderly population projected to increase from 320 million to 390 million by 2030, driving demand for anti-aging products [19]. - Younger generations are also increasingly aware of anti-aging needs, creating a dual demand for NMN products [19]. Technological Innovations - Advances in synthesis methods, particularly the full enzyme method, are driving down costs and improving product quality in the NMN industry [21][22]. - Innovations in delivery technologies are enhancing the bioavailability of NMN, ensuring better absorption and user experience [22]. Application Areas - NMN is primarily used in health supplements and cosmetics, with health supplements accounting for nearly 90% of the market share [24][28]. - Future applications are expected to expand into pet nutrition, medical health, and agricultural technology, opening new growth avenues [24][28]. Market Size and Growth - The NMN market in China is expected to exceed 3 billion yuan by 2025, driven by increasing regulatory support and expanding applications [28][32]. - The market is currently dominated by health supplements and cosmetics, with significant growth potential in other sectors as regulations ease [28][32]. Sales Channels - NMN products are primarily sold through cross-border e-commerce and private channels, with cross-border e-commerce accounting for 60%-70% of market share [35][34]. Certification and Standards - The "blue hat" certification for health foods in China represents the highest standard for NMN products, indicating safety and compliance [37]. Challenges and Opportunities - The NMN industry faces challenges such as exaggerated claims, lack of consumer awareness, and technological iterations, necessitating a focus on compliance and innovation [61][63]. - Companies are encouraged to innovate their business models and extend their value chains to enhance competitiveness [66].

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining global attention in the health industry due to its potential in anti-aging, DNA repair, and metabolic regulation, with significant advancements in regulatory approval and market potential expected by 2025 [1][2]. Group 1: NMN Definition and Function - NMN is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can rapidly increase NAD+ levels in the body, playing a vital role in anti-aging, cardiovascular health, and cognitive function [4][6]. Group 2: Global Regulatory Landscape - By 2025, NMN's global compliance process is expected to accelerate, with major markets like the US, Japan, Canada, and Australia confirming its legal status through various regulatory pathways [1][2]. - In China, NMN has not yet received approval as a drug or health food, but it has been recognized as a new cosmetic ingredient, laying the groundwork for future regulatory developments [1][17]. Group 3: Market Demand Drivers - The aging population in China is projected to grow significantly, with the elderly population expected to increase from 320 million to 390 million between 2025 and 2030, driving the "silver economy" and demand for anti-aging products [19]. - Younger generations, particularly those born in the 1990s, are increasingly aware of anti-aging needs, creating a dual demand for NMN products [19]. Group 4: Technological Innovations - Continuous innovations in synthesis, quality testing, and delivery methods are driving the NMN industry forward, with full enzyme methods significantly enhancing production efficiency and reducing costs [21][22]. - The establishment of testing standards is raising industry entry barriers, promoting market development [22]. Group 5: Current Market Status - The NMN market in China has been expanding rapidly since its large-scale entry in 2020, with expectations to exceed 3 billion yuan by 2025 [28]. - NMN is primarily used in health supplements (approximately 90% of applications) and cosmetics (10-20%), with potential future applications in pet nutrition, medical health, and agricultural technology [24][28]. Group 6: Sales Channels - NMN products are mainly sold through cross-border e-commerce and private channels, with cross-border e-commerce accounting for 60-70% of the market share [35]. Group 7: Industry Challenges - The NMN industry faces challenges such as exaggerated claims, lack of consumer awareness, and the need for technological iteration, necessitating a focus on compliance and innovation to unlock market potential [61][63].

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field that disrupts traditional production methods, presenting it as a new growth point for optimizing industrial structure and transforming economic models [1]. Group 1: Current Status and Trends - The "2025 China Synthetic Biomanufacturing Industry Development White Paper" was officially released on August 1, highlighting the current state and trends of biomanufacturing [1]. - The report analyzes the global biomanufacturing industry, including key platform facilities and a comparative study of the US and China in this sector [7]. Group 2: Policy Landscape - The white paper outlines major domestic and international policies affecting biomanufacturing from 2024 to 2025, providing insights into regulatory frameworks [7]. Group 3: Industry Map and Applications - It presents a comprehensive map of the Chinese biomanufacturing industry and identifies key application areas, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [7]. Group 4: Key Enterprises - The report selects ten leading enterprises in the Chinese biomanufacturing sector and details the strategic directions of 15 listed companies in synthetic biology [7][8]. Group 5: Investment and Challenges - The document discusses the investment landscape in synthetic biology from 2024 to mid-2025 and addresses the challenges faced by the biomanufacturing industry in China, along with proposed countermeasures [7].